U.S. Patent 9,789,064: Claim Scope, Patent Landscape, Exclusivity and Generic Entry Risk

U.S. Patent No. 9,789,064 protects biodegradable PLA or PLGA microcapsules containing specified peptide analogs and triethyl citrate (TEC) at 2.7% to 4.4% by total microcapsule-component weight. Its strongest protection is directed to the combination of a narrowly defined TEC concentration and reduced initial peptide release. The patent covers both therapeutic administration methods and a microcapsule composition.

The claims do not broadly cover every leuprolide, triptorelin, octreotide, or other peptide depot. A potentially infringing product would generally need to use the claimed polymer system, contain TEC within the stated range, and satisfy the functional release limitation.

What does U.S. Patent 9,789,064 protect?

The patent has three independent claims:

Claim	Claim type	Principal subject matter
1	Method of treatment or delivery	Administration of PLA or PLGA microcapsules containing an LHRH analog and 2.7%-4.4% TEC
3	Manufacturing and administration method	Formation of peptide-containing microcapsules using dissolved polymer, TEC, an alkyl derivative, and a hardening medium
10	Composition	A microcapsule containing leuprolide, octreotide, or triptorelin, PLA or PLGA, and 2.7%-4.4% TEC

The central technical limitation is the presence of TEC as a release-modulating additive. The claims require TEC to reduce the initial release rate compared with an otherwise identical microcapsule without TEC. This is commonly associated with control of the initial burst effect in biodegradable peptide microspheres.

What products and active ingredients fall within the claims?

The independent method claims identify the following LHRH or LHRH-related peptide analogs:

Triptorelin
Leuprolide
Goserelin
Buserelin
Cetrorelix

Claim 10 has a different active-ingredient list:

Leuprolide
Octreotide
Triptorelin

The difference matters. A microcapsule containing goserelin, buserelin, or cetrorelix may fall within claims 1 or 3 if the other limitations are met, but those compounds are not expressly included in claim 10.

The claims also require a biodegradable polymer selected from:

A polylactic acid polymer, or
A lactic-co-glycolic copolymer, commonly referred to as PLGA

The patent therefore targets injectable or implantable controlled-release systems rather than conventional oral, transdermal, or immediate-release peptide formulations.

How narrow is the 2.7% to 4.4% TEC limitation?

The TEC range is the principal numerical boundary in the patent.

Feature	Claimed requirement
Additive	Triethyl citrate
Concentration	2.7% to 4.4% by total weight of microcapsule components
Function	Modulates release and reduces initial release versus a matching formulation without TEC
Polymer	PLA or PLGA
Active ingredient	Specified peptide analogs, depending on claim

A formulation containing 2.6% TEC would fall outside the literal numerical range. A formulation containing 4.5% TEC would also fall outside the literal range. That does not eliminate all litigation risk because a patentee could assert infringement under the doctrine of equivalents, although the strength of that theory would depend on prosecution history, disclosed criticality of the range, prior-art amendments, and the technical effect at the accused concentration.

The range creates a design-around opportunity, but concentration alone may not be sufficient. A competitor would also need to evaluate whether its formulation uses a different release mechanism, polymer, additive, manufacturing process, or peptide.

What do claims 1 and 3 cover?

Claim 1: administration method

Claim 1 requires:

A subject in need of treatment.
Administration of microcapsules.
An included peptide from the specified LHRH analog group.
PLA or PLGA as the polymer.
TEC at 2.7%-4.4% by total component weight.
A reduction in the initial release rate compared with an otherwise identical formulation without TEC.

Claim 1 is not limited to a particular dose, injection site, treatment duration, particle size, peptide loading, or commercial product. Dependent claims add narrower limitations.

Claim 2 limits the PLGA lactate-to-glycolate ratio to 99:1 through 10:90. Claim 6 narrows the ratio to 1:1. Claim 7 specifies a PLGA molecular weight of 50,000. Claims 8 and 9 narrow the peptide to leuprolide and leuprolide acetate, respectively.

A leuprolide depot using a 1:1 PLGA polymer with a molecular weight of 50,000 and TEC within the claimed range would face the highest literal overlap with the dependent-claim structure.

Claim 3: process-plus-treatment method

Claim 3 combines manufacturing steps with subsequent administration. It requires:

Dissolving PLA or PLGA and TEC in a solvent;
Adding the peptide to create a suspension;
Adding an alkyl derivative to deposit polymer and TEC on the peptide;
Adding the suspension to a non-solvent or hardening medium;
Isolating the microcapsules; and
Administering enough microcapsules to provide a therapeutic effect.

Claim 5 identifies silicon oil as the alkyl derivative. The process claim is narrower than claim 1 because an accused manufacturer must practice the specified preparation sequence, or a legally equivalent sequence, before administration.

The text supplied for claim 3 contains a potential antecedent-reference problem. Step (iv) refers to “the suspension obtained in step (ii)” even though step (iii) modifies the suspension. That wording may generate claim-construction disputes over whether the suspension used in the hardening step must include the alkyl derivative treatment described in step (iii). The practical effect would depend on the patent specification, prosecution history, and claim-construction record.

What does claim 10 protect?

Claim 10 is the broadest commercially relevant composition claim in the supplied set because it does not require administration to a patient. It covers a microcapsule containing:

Leuprolide, octreotide, or triptorelin;
PLA or PLGA; and
TEC at 2.7%-4.4% by total microcapsule-component weight.

The claim also requires the release-modulation and reduced-initial-release characteristics.

A composition claim can create a more direct infringement theory than a method-of-treatment claim if an accused product is made, imported, offered for sale, or sold in the United States. The claim does not appear limited to a particular indication. For leuprolide and triptorelin, the commercial relevance is strongest in long-acting endocrine therapies. For octreotide, the relevant market is controlled-release somatostatin analog formulations.

How does the patent compare with conventional peptide depot patents?

The patent is narrower than early peptide depot patents that broadly claim biodegradable polymer microspheres or sustained-release compositions. Its differentiation is based on the use of TEC within a specified concentration range and the associated reduction in initial release.

Patent category	Typical protected subject matter	Relationship to U.S. 9,789,064
Peptide-polymer depot patents	General microspheres containing peptides in PLA or PLGA	Potentially earlier blocking art and possible validity references
Polymer composition patents	Specific lactide:glycolide ratios, molecular weights, particle properties	Overlap with claims 2, 4, 6 and 7
Manufacturing patents	Solvent evaporation, coacervation, hardening and encapsulation processes	Relevant to claim 3
Plasticizer or additive patents	Use of TEC or other excipients to alter polymer properties or release	Closest technical prior-art category
Product-specific patents	Leuprolide, triptorelin or octreotide depot products	May overlap commercially without sharing the same formulation limitations
Method-of-use patents	Treatment of prostate cancer, endometriosis, uterine fibroids, precocious puberty or acromegaly	Separate protection from the formulation claims

The patent does not appear, from the supplied claims, to protect the peptide active ingredient itself, the indication, or the use of a particular delivery device. Its value depends on whether the commercial formulation requires TEC in the claimed range.

What are the main validity and enforceability issues?

Written description and enablement

The specification would need to support the full combination of:

Five LHRH analogs in claims 1 and 3;
Three active ingredients in claim 10;
PLA and the full PLGA ratio range;
TEC throughout 2.7%-4.4%; and
The claimed reduction in initial release.

If the disclosure contains only a small number of examples, an accused infringer could challenge whether the entire genus and numerical range were adequately supported.

Obviousness

The main obviousness question is whether a skilled formulator would have selected TEC as a plasticizer or release modifier and tested concentrations within the claimed range. A stronger validity position would exist if the specification shows an unexpected reduction in initial release at the claimed range, especially if nearby concentrations did not provide the same result.

Functional limitation

The requirement that TEC “produces” a reduction in initial release is important. It can narrow the claims if a formulation contains TEC but does not produce the claimed comparative result. The comparison must generally be made against an identical microcapsule without TEC, although the patent specification may define the testing conditions.

Patent exhaustion and authorized sales

An authorized sale of a patented microcapsule product may exhaust certain patent rights in the specific article sold. Exhaustion would not necessarily eliminate separate method-of-use or process claims against other conduct. The commercial impact depends on the product, transaction, and asserted claim.

When does U.S. Patent 9,789,064 lose exclusivity?

The issue date of U.S. Patent 9,789,064 was October 17, 2017. Its expiration date cannot be calculated from the claims or issue date alone. U.S. patent term is generally measured from the earliest effective nonprovisional filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and other statutory rules (35 U.S.C. §§ 154, 156).

The following records control the operative expiration date:

Term issue	Relevance
Earliest effective nonprovisional filing date	Establishes the ordinary 20-year term
Patent-term adjustment	Can extend the term for qualifying USPTO delay
Patent-term extension	May apply to eligible regulatory review periods, although applicability depends on the patented product and statutory requirements
Terminal disclaimer	Can shorten the term to match an earlier patent
Maintenance fees	Nonpayment can cause expiration before the ordinary term
Reexamination or post-grant proceedings	May cancel, amend or confirm claims

A patent expiration date should therefore be taken from the USPTO Patent Center record and the official patent-term calculation, not inferred from the 2017 grant date.[1]

What is the Orange Book status of this patent?

The supplied claims do not establish whether U.S. Patent 9,789,064 is listed in the FDA Orange Book.

Orange Book listing is product-specific. FDA listing generally requires an NDA holder to submit a patent that claims the approved drug substance, drug product, or an approved method of use, together with the required certification or statement under the Hatch-Waxman framework.[2] A formulation patent may be listable if it claims the approved drug product, but the patent number alone does not prove listing.

The distinction is commercially significant:

An Orange Book-listed patent can support a Paragraph IV certification and, if timely sued, a statutory 30-month stay.
A non-listed formulation or process patent does not create the same automatic Hatch-Waxman stay.
A patent may still support infringement litigation even if it is absent from the Orange Book.

For products containing leuprolide, triptorelin, or octreotide, the relevant Orange Book analysis must be performed at the NDA and approved-product level. Patent 9,789,064 should not be treated as an Orange Book barrier solely because it claims a peptide microcapsule.

What Paragraph IV risks exist for generic leuprolide products?

A generic applicant could challenge the patent through a Paragraph IV certification if the patent is listed against the relevant reference product and the applicant seeks approval before expiration.

Potential certification positions include:

The generic does not contain TEC.
TEC is present below 2.7% or above 4.4%.
The generic uses a polymer outside PLA or PLGA.
The formulation does not produce the claimed comparative reduction in initial release.
The product contains a peptide not covered by the relevant claim.
The manufacturing process does not practice claim 3.
The patent claims are invalid for anticipation, obviousness, lack of written description, enablement, indefiniteness, or another statutory ground.

A generic using the same or substantially similar microsphere technology would face greater risk than a product using a different polymer, different excipient, or a non-microsphere delivery platform.

What manufacturing and intellectual-property barriers matter?

The patent’s commercial relevance extends beyond TEC. Peptide microsphere development has substantial process sensitivity involving:

Peptide stability during solvent exposure;
Encapsulation efficiency;
Particle-size distribution;
Residual solvent limits;
Initial burst release;
Long-term release kinetics;
Sterility and aseptic processing;
Scale-up reproducibility;
Polymer molecular-weight distribution; and
Batch-to-batch equivalence.

A competitor may avoid literal infringement but still face separate patents covering polymer selection, solvent systems, particle fabrication, injection devices, reconstitution systems, or approved methods of use. Freedom to operate therefore requires a family-by-family review rather than an analysis of Patent 9,789,064 in isolation.

Which companies and products are most commercially relevant?

The competitive landscape includes companies developing or marketing long-acting peptide depots, including manufacturers associated with:

Leuprolide depot products;
Triptorelin depot products;
Octreotide long-acting formulations;
Goserelin implants;
Alternative polymer microspheres;
In situ gel systems; and
Non-polymeric sustained-release delivery systems.

Relevant commercial products may include Lupron Depot, Eligard, Fensolvi, Trelstar, Sandostatin LAR and related products, although the existence of a product in the same therapeutic class does not establish infringement. Each product requires formulation-level testing and patent-family review.

What is the overall patent strength?

The patent has moderate potential strength as a formulation-specific patent and limited breadth as a general peptide-depot patent.

Factor	Assessment
Numerical specificity	Stronger against formulations within 2.7%-4.4% TEC
Polymer limitation	Narrows the field to PLA and PLGA systems
Functional release limitation	Can support technical distinction but may complicate proof
Active-ingredient coverage	Broad in method claims; narrower in composition claim
Manufacturing claim	Potentially useful against contract manufacturers and vertically integrated competitors
Design-around potential	Meaningful through excipient, concentration, polymer or process changes
Orange Book value	Cannot be inferred from the patent claims
Generic litigation risk	Highest for substantially equivalent PLGA/TEC microspheres
Biosimilar risk	Not applicable in the conventional Purple Book sense because the claimed products are peptide drugs, not biologics subject to the biosimilar pathway

The patent is most important where a competitor’s formulation replicates the claimed TEC concentration and release profile. It is less likely to block a product based on a different controlled-release technology.

Key Takeaways

U.S. Patent 9,789,064 centers on TEC-containing PLA or PLGA microcapsules for controlled peptide release.
The critical concentration is 2.7% to 4.4% by total microcapsule-component weight.
Claims 1 and 3 cover administration methods; claim 3 also covers a defined manufacturing sequence.
Claim 10 covers microcapsules containing leuprolide, octreotide or triptorelin.
Claims 2, 4, 6 and 7 narrow the polymer composition by lactate:glycolate ratio and molecular weight.
The patent does not, from the supplied claims, establish protection for the peptide active ingredient, indication or delivery device.
The largest validity issues are obviousness, support for the full peptide and polymer genera, and proof of the functional release limitation.
The patent’s exact expiration date requires the USPTO term record and cannot be derived from the issue date alone.
Orange Book listing and Paragraph IV exposure are product- and NDA-specific.
The most credible design-arounds involve removing TEC, moving outside the claimed range, changing the polymer system, or adopting a different release platform.

FAQs

Can a leuprolide product infringe Patent 9,789,064 without using TEC?

No literal infringement of the supplied claims would ordinarily exist without TEC because TEC is an express limitation of claims 1, 3 and 10. Other patents could still cover the same leuprolide depot.

Does a PLGA ratio of 50:50 create higher infringement risk?

Yes. A 50:50 lactate-to-glycolate ratio falls within the 99:1 to 10:90 range and is expressly identified in dependent claim 6. The TEC concentration and release effect must also be satisfied.

Does claim 10 cover a bulk polymer formulation before microcapsule formation?

The claim is directed to “a microcapsule.” A bulk polymer-peptide solution would not satisfy that structural limitation unless it is legally characterized as the claimed microcapsule or is used in a manner implicating another claim.

Are octreotide microspheres covered by claims 1 or 3?

Not based on the supplied language. Claims 1 and 3 list LHRH peptide analogs. Octreotide appears expressly in claim 10, which is the relevant composition claim.

Can a competitor avoid claim 3 by outsourcing manufacture?

Outsourcing does not automatically eliminate risk. Liability may depend on who performs the claimed steps, who imports or sells the resulting microcapsules, and whether method, composition, inducement or contributory-infringement theories apply.

References

United States Patent and Trademark Office. (2017). U.S. Patent No. 9,789,064.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
35 U.S.C. § 154. Patent term.
35 U.S.C. § 156. Extension of patent term.
21 U.S.C. § 355. New drug applications and abbreviated applications.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Spain	9902768	Dec 17, 1999

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	234608	⤷ Start Trial
Australia	2173501	⤷ Start Trial
Australia	774680	⤷ Start Trial
Brazil	0008197	⤷ Start Trial
Brazil	PI0008197	⤷ Start Trial
Canada	2362769	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,789,064

Summary for Patent: 9,789,064